Proehl Gerald T's Form 4 filing
Dermata Therapeutics, Inc. (DRMA) · filed Aug 18, 2026
- Accession no.
- 0001493152-26-039048
- Filed
- Aug 18, 2026, 5:25 PM ET
- Trade date
- Aug 16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 5 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Proehl Gerald TCIK 0001279191 | Director, Officer (PRESIDENT, CHAIRMAN, CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +170,068 | –F2 | – | 292,631 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +1,360,544 | –F2 | – | 1,360,544 | Indirect | |
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +1,360,544 | –F2 | – | 1,360,544 | Indirect | |
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +170,068 | –F2 | – | 170,068 | Indirect | |
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +170,068 | –F2 | – | 170,068 | Indirect | |
| Aug 16, 2026 | Common Stock | AGrant or awardAcquired | +1,360,544 | –F2 | – | 1,360,544 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469.
Referenced by the price of 1 transaction in Table I and 5 transactions in Table II.